Galectin Therapeutics Inc.

NasdaqCM:GALT Rapport sur les actions

Capitalisation boursière : US$136.9m

Galectin Therapeutics Croissance future

Future contrôle des critères 0/6

Galectin Therapeutics devrait augmenter ses bénéfices de 8% par an. Le BPA devrait augmenter de 12.1% par an.

Informations clés

8.0%

Taux de croissance des bénéfices

12.09%

Taux de croissance du BPA

Biotechs croissance des bénéfices25.0%
Taux de croissance des recettesn/a
Rendement futur des capitaux propresn/a
Couverture par les analystes

Low

Dernière mise à jour15 May 2026

Mises à jour récentes de la croissance future

Recent updates

Seeking Alpha • Oct 12

Galectin rises as FDA approves to begin human trial of combination immunotherapy in head and neck cancer

Galectin Therapeutics (NASDAQ:GALT) said on Wednesday it had filed an investigational New Drug application with the U.S. Food and Drug Administration for belapectin in combination with a checkpoint inhibitor to treat Head and Neck cancer. (GALT) has risen 3.7% premarket. The company said it also received a study may proceed letter for a Phase 2 clinical trial of Belapectin in combination with Pembrolizumab as first-line treatment in subjects with recurrent/metastatic PD-L1 Positive Squamous Cell Carcinoma of the Head and Neck.
Seeking Alpha • Aug 15

Galectin Therapeutics GAAP EPS of -$0.16

Galectin Therapeutics press release (NASDAQ:GALT): Q2 GAAP EPS of -$0.16. As of June 30, 2022, the Company had $24.2M of cash and cash equivalents. The company believes it has sufficient cash, including availability under its new $60M line of credit, to fund currently planned operations and research and development activities through at least December 31, 2024.
Seeking Alpha • Jul 11

Galectin: Ability To Potentially Target Unmet Medical Need

Results from the phase 3 NAVIGATE study using Belapectin for the treatment of patients with NASH Cirrhosis without esophageal varices are expected in Q1 of 2024. If the primary endpoint of the phase 3 NAVIGATE study is met, ability to advance Belapectin towards other indications such as Pulmonary arterial hypertension, advanced NASH fibrosis, and Lung/Kidney disease. An IND filing to initiate a randomized placebo controlled phase 2 study using Belapectin plus Keytruda for the treatment of patients with Head & Neck cancer is expected in 2022. Galectin had $39.6 million in cash as of December 31, 2021; enough cash to fund its operations until at least March 31, 2023. Galectin Therapeutics Inc. (GALT) is a great speculative biotech play to look into. That's because it is focused on a population with a huge unmet medical need. It is currently enrolling and treating non-alcoholic steatohepatitis ((NASH)) cirrhosis patients with its Belapectin drug in a phase 3 study known as NAVIGATE. A prior phase 2 study established proof of concept in a subpopulation of NASH cirrhosis patients with varices. That is, the drug worked well in this specific patient population. However, when looking at the overall NASH cirrhosis population the entire trial failed. The thing is that if this study ends up succeeding, it would establish proof of concept in using Belapectin as an anti-fibrotic treatment towards other indications such as: Lung/Kidney disease, advanced NASH fibrosis, pulmonary arterial hypertension ((PAH)) and many others. What is also good about Belapectin is that it can also be advanced for oncology as well. As such, Galectin Therapeutics has already selected to advance this drug in combination with Keytruda for the treatment of patients with head and neck cancer. It intends to file an IND in 2022 to initiate a more advanced phase 2 study just focused on using this combination to treat this patient population. Based on the potential with Belapectin as an anti-fibrotic drug, plus the ability to possibly expand into oncology, these are the reasons why I believe that Galectin Therapeutics is a great speculative biotech play to look into. Belapectin For The Treatment Of Patients With NASH Cirrhosis & Other Fibrotic Disorders The main program in the pipeline is the use of Belapectin for the treatment of patients with NASH Cirrhosis. Cirrhosis occurs when the scarring (fibrosis) of the liver is at a late stage in the cycle. The liver is severely injured and it keeps trying to repair itself. It can be caused by many things, like Hepatitis and chronic alcohol drinking. Another item that has been prevalent is eating a lot of fats. What do I mean by this? Well, as I will explain below, Galectin Therapeutics is also going after NASH fibrosis. People who obtain non-alcoholic fatty liver disease ((NAFLD)) can develop Non-alcoholic steatohepatitis ((NASH)). If the inflammation and scarring of the liver becomes far more severe, then that becomes cirrhosis. Cirrhosis is a major problem and may eventually lead to liver failure. Another item to note is that the company ran a proof of concept study known as NASH-CX, which I will talk about below in detail. However, it only saw a benefit of patients of NASH cirrhosis for 50% of the population. More about this below, but just know that this program has massive potential. Galectin was able to show that Belapectin was able to help about 50% of the NASH cirrhosis population it treated. This accomplishment was observed from the phase 2b NASH-CX trial. This is a study that treated up to 162 patients with NASH cirrhosis who were randomized to receive either Belapectin or placebo. The breakdown of the dosing was as follows: 2 mg/kg of belapectin 8 mg/kg of belapectin Placebo Patients receive one of these doses for a total of 62 weeks. The thing to note is that this proof of concept study heavily focused on well-compensated NASH cirrhosis and not decompensated NASH cirrhosis. What's the difference between well-compensated cirrhosis and decompensated NASH cirrhosis? In compensated NASH cirrhosis patients are somewhat functioning albeit not that great. These patients don't have symptoms and their liver does still function. For those with decompensated NASH cirrhosis, the liver is heavily damaged and is not working much if at all. It is said that when a patient is diagnosed with decompensated NASH cirrhosis, they have a life expectancy between 1 and 3 years. That's why the company recruited patients who did have NASH cirrhosis but had not yet reached to decompensated status. The primary endpoint of the study was a reduction in HVPG. HVPG stands for Hepatic venous pressure gradient. It is used to measure the portal hypertension of the liver. That is the vein that carries blood from the digestion organs to the liver. When this is under pressure, it means the disease is far more advanced. The goal of Belapectin is to reduce this measure. The final end result was that 50% patients given Belapectin had achieved a significant reduction in HVPG compared to placebo. That is, those who took 2 mg/kg Belapectin had achieved a 44% reduction, compared to only 15% for those on placebo. This gave a statistically significant p-value of p=0.02. However, the main thing to point out is that this was for patients without varices. What is varices? Basically, varices means an enlarged vein in the liver that is blocked. For the other 50% of patients with varices, Belapectin did not achieve statistical significance. In my opinion, at least the company can still target 50% of the cirrhosis population. Of course, that is that the ongoing late-stage study pans out. The statistical significance of using Belapectin to treat NASH cirrhosis patients was very good. Good enough that the FDA had allowed Galectin to initiate a late-stage phase 2b/3 study known as NAVIGATE. This study intends to enroll up to 315 NASH patients with NASH cirrhosis without esophageal varices. The goal is to attempt to prevent varices from even forming in the liver in the first place. Patients are going to be given either 2 mg/kg of Belapectin , 4 mg/kg of Belapactin or placebo. This phase 2b/3 study was initiated back in June of 2020. As you guessed, the primary endpoint will be to determine the number of varices formed at the end of the treatment period. The less varices developed with patients given belapectin compared to placebo, the greater chance that the study will succeed. As long as belapectin achieves statistical significance for this patient population over placebo, then that opens the door to other fibrotic indications. The company notes that it intends to possibly seek for accelerated approval and may even seek a partnership to help fund it commercially should it need to eventually be marketed. The biggest downside, though, is that this study is a long one. That's because the expected completion date of the study itself is not expected until June of 2023. Thus, interim results from this late-stage NAVIGATE study won't be released until around Q1 of 2024. Financials According to the 10-Q SEC Filing, Galectin Therapeutics had cash and cash equivalents of $39.6 million as of December 31, 2021. However, it received $10 million in proceeds from an unsecured convertible promissory note from its Board Chairman Richard E. Uihlein. I don't think it needs to worry about funding too much, especially with the amount of cash this Board Chairman has put in. It is said that Galectin received a total of $30 million in unsecured promissory notes from Mr. Uihlein in 2021. Not only that, but because its program is highly focused on Belapectin in the ongoing phase 3 NAVIGATE study, it believes it has enough cash to fund its operations until March 31, 2023. Around that point, it will need to obtain additional funding. If it can't get any more cash from Mr. Uihlein again, then I believe it will just have the typical biotech option of selling shares of its common stock on the open market to obtain funding. If it does need to go this route, my guess is that it won't need to do so until the end of 2022. Risks To Business There are several risks that investors should be aware of before taking a position in this speculative biotech. The first risk relates to the phase 3 NAVIGATE trial itself using Belapectin for the treatment of patients with NASH cirrhosis without esophageal varices. Even though the phase 2 study established statistical significance for Belpectin in this subpopulation of NASH cirrhosis patients, there is no guarantee that the same will be achieved in the NAVIGATE trial. If the study fails, not only do I predict that the stock will trade below $1 per share, but also that it will force it to move all its efforts towards oncology.
Seeking Alpha • Jul 01

Galectin: Pursuing A Subset In The NASH Space

Galectin failed a phase 2 trial in 2017. However, the trial saw certain interesting features in a subset of patients. Galectin is pursuing this subset in another trial.
Article d’analyse • Feb 25

Read This Before Buying Galectin Therapeutics, Inc. (NASDAQ:GALT) Shares

It is not uncommon to see companies perform well in the years after insiders buy shares. On the other hand, we'd be...
Article d’analyse • Jan 21

Is Galectin Therapeutics (NASDAQ:GALT) In A Good Position To Deliver On Growth Plans?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Article d’analyse • Dec 09

How Much Of Galectin Therapeutics, Inc. (NASDAQ:GALT) Do Insiders Own?

Every investor in Galectin Therapeutics, Inc. ( NASDAQ:GALT ) should be aware of the most powerful shareholder groups...

Prévisions de croissance des bénéfices et des revenus

NasdaqCM:GALT - Estimations futures des analystes et données financières antérieures (USD Millions )
DateRecettesLes revenusFlux de trésorerie disponibleCash from OpMoy. Nombre d'analystes
12/31/2027N/A-23N/AN/A1
12/31/2026N/A-25N/AN/A1
3/31/2026N/A-26-20-20N/A
12/31/2025N/A-31-24-24N/A
9/30/2025N/A-37-31-31N/A
6/30/2025N/A-40-36-36N/A
3/31/2025N/A-45-37-37N/A
12/31/2024N/A-47-42-42N/A
9/30/2024N/A-45-34-34N/A
6/30/2024N/A-48-33-33N/A
3/31/2024N/A-45-34-34N/A
12/31/2023N/A-45-33-33N/A
9/30/2023N/A-45-36-36N/A
6/30/2023N/A-40-36-36N/A
3/31/2023N/A-40-34-34N/A
12/31/2022N/A-39-31-31N/A
9/30/2022N/A-35-31-31N/A
6/30/2022N/A-35-27-27N/A
3/31/2022N/A-34-26-26N/A
12/31/2021N/A-31-24-24N/A
9/30/2021N/A-31-23-23N/A
6/30/2021N/A-29-26-26N/A
3/31/2021N/A-26-23-23N/A
12/31/2020N/A-24-21-21N/A
9/30/2020N/A-21-19-19N/A
6/30/2020N/A-18-12-12N/A
3/31/2020N/A-15-12-12N/A
12/31/2019N/A-20N/A-11N/A
9/30/2019N/A-18N/A-9N/A
6/30/2019N/A-19N/A-9N/A
3/31/2019N/A-20N/A-10N/A
12/31/2018N/A-15N/A-10N/A
9/30/2018N/A-14N/A-12N/A
6/30/2018N/A-16N/A-14N/A
3/31/2018N/A-17N/A-16N/A
12/31/2017N/A-17N/A-16N/A
9/30/2017N/A-20N/A-17N/A
6/30/2017N/A-20N/A-17N/A
3/31/2017N/A-21N/A-17N/A
12/31/2016N/A-22N/A-16N/A
9/30/2016N/A-22N/A-16N/A
6/30/2016N/A-24N/A-18N/A
3/31/2016N/A-23N/A-16N/A
12/31/2015N/A-21N/A-17N/A
9/30/2015N/A-20N/A-15N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: GALT devrait rester non rentable au cours des 3 prochaines années.

Bénéfices vs marché: GALT devrait rester non rentable au cours des 3 prochaines années.

Croissance élevée des bénéfices: GALT devrait rester non rentable au cours des 3 prochaines années.

Chiffre d'affaires vs marché: Données insuffisantes pour déterminer si les revenus de GALT devraient croître plus rapidement que le marché US.

Croissance élevée des revenus: GALT ne devrait pas générer de revenus l'année prochaine.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Données insuffisantes pour déterminer si le retour sur capitaux propres de GALT devrait être élevé dans 3 ans

Découvrir les entreprises en croissance

7D

1Y

7D

1Y

7D

1Y

Analyse de l'entreprise et données financières

DonnéesDernière mise à jour (heure UTC)
Analyse de l'entreprise2026/05/20 02:50
Cours de l'action en fin de journée2026/05/20 00:00
Les revenus2026/03/31
Revenus annuels2025/12/31

Sources de données

Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.

PaquetDonnéesCadre temporelExemple de source américaine *
Finances de l'entreprise10 ans
  • Compte de résultat
  • Tableau des flux de trésorerie
  • Bilan
Estimations consensuelles des analystes+3 ans
  • Prévisions financières
  • Objectifs de prix des analystes
Prix du marché30 ans
  • Cours des actions
  • Dividendes, scissions et actions
Propriété10 ans
  • Actionnaires principaux
  • Délits d'initiés
Gestion10 ans
  • L'équipe dirigeante
  • Conseil d'administration
Principaux développements10 ans
  • Annonces de l'entreprise

* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.

Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.

Modèle d'analyse et flocon de neige

Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.

Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.

Indicateurs de l'industrie et du secteur

Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.

Sources des analystes

Galectin Therapeutics Inc. est couverte par 5 analystes. 1 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.

AnalysteInstitution
Keay NakaeAscendiant Capital Markets LLC
Mayank MamtaniB. Riley Securities, Inc.
Matthew KellerH.C. Wainwright & Co.